Innoviva, Inc. (INVA)
USD 17.5
(2.34%)
USD 17.5
(2.34%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 255.56 Million USD | -26.32% |
| 2022 | 346.83 Million USD | 79.59% |
| 2021 | 193.12 Million USD | 38.91% |
| 2020 | 139.03 Million USD | 40.4% |
| 2019 | 99.02 Million USD | -69.1% |
| 2018 | 320.43 Million USD | -39.08% |
| 2017 | 526.02 Million USD | -12.05% |
| 2016 | 598.07 Million USD | 1.53% |
| 2015 | 589.09 Million USD | -6.32% |
| 2014 | 628.83 Million USD | 336.72% |
| 2013 | 143.99 Million USD | 85.43% |
| 2012 | 77.65 Million USD | -39.24% |
| 2011 | 127.79 Million USD | 1253.43% |
| 2010 | 9.44 Million USD | -92.47% |
| 2009 | 125.41 Million USD | 55.49% |
| 2008 | 80.65 Million USD | 193.9% |
| 2007 | -85.89 Million USD | -19.7% |
| 2006 | -71.76 Million USD | -49.78% |
| 2005 | -47.91 Million USD | 50.61% |
| 2004 | -97.01 Million USD | -247.98% |
| 2003 | -27.87 Million USD | 61.68% |
| 2002 | -72.74 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 233.71 Million USD | -13.75% |
| 2024 Q1 | 270.97 Million USD | 6.03% |
| 2023 Q1 | 300.64 Million USD | -13.32% |
| 2023 FY | 255.56 Million USD | -26.32% |
| 2023 Q2 | 275.26 Million USD | -8.44% |
| 2023 Q3 | 268.88 Million USD | -2.32% |
| 2023 Q4 | 255.56 Million USD | -4.95% |
| 2022 Q3 | 242.89 Million USD | -6.38% |
| 2022 Q2 | 259.44 Million USD | -38.5% |
| 2022 Q4 | 346.83 Million USD | 42.79% |
| 2022 Q1 | 421.88 Million USD | 118.45% |
| 2022 FY | 346.83 Million USD | 79.59% |
| 2021 FY | 193.12 Million USD | 38.91% |
| 2021 Q1 | 104.83 Million USD | -24.59% |
| 2021 Q2 | 346.72 Million USD | 230.72% |
| 2021 Q3 | 257.18 Million USD | -25.83% |
| 2021 Q4 | 193.12 Million USD | -24.91% |
| 2020 Q4 | 139.03 Million USD | 245.06% |
| 2020 Q3 | -95.84 Million USD | -200.29% |
| 2020 Q2 | -31.91 Million USD | -217.47% |
| 2020 Q1 | 27.17 Million USD | -72.56% |
| 2020 FY | 139.03 Million USD | 40.4% |
| 2019 Q1 | 321.13 Million USD | 0.22% |
| 2019 FY | 99.02 Million USD | -69.1% |
| 2019 Q2 | 244.72 Million USD | -23.8% |
| 2019 Q3 | 215.69 Million USD | -11.86% |
| 2019 Q4 | 99.02 Million USD | -54.09% |
| 2018 FY | 320.43 Million USD | -39.08% |
| 2018 Q4 | 320.43 Million USD | -3.59% |
| 2018 Q1 | 457.45 Million USD | -13.04% |
| 2018 Q2 | 399.3 Million USD | -12.71% |
| 2018 Q3 | 332.38 Million USD | -16.76% |
| 2017 Q3 | 465.03 Million USD | -11.63% |
| 2017 Q1 | 549.22 Million USD | -8.17% |
| 2017 FY | 526.02 Million USD | -12.05% |
| 2017 Q4 | 526.02 Million USD | 13.12% |
| 2017 Q2 | 526.25 Million USD | -4.18% |
| 2016 Q2 | 612.6 Million USD | 5.13% |
| 2016 FY | 598.07 Million USD | 1.53% |
| 2016 Q4 | 598.07 Million USD | -5.04% |
| 2016 Q3 | 629.8 Million USD | 2.81% |
| 2016 Q1 | 582.73 Million USD | -1.08% |
| 2015 FY | 589.09 Million USD | -6.32% |
| 2015 Q4 | 589.09 Million USD | -11.46% |
| 2015 Q3 | 665.33 Million USD | 12.98% |
| 2015 Q2 | 588.89 Million USD | -0.34% |
| 2015 Q1 | 590.87 Million USD | -6.04% |
| 2014 Q3 | 585.53 Million USD | 10.59% |
| 2014 FY | 628.83 Million USD | 336.72% |
| 2014 Q4 | 628.83 Million USD | 7.4% |
| 2014 Q1 | 162.22 Million USD | 12.66% |
| 2014 Q2 | 529.44 Million USD | 226.37% |
| 2013 Q4 | 143.99 Million USD | 24.55% |
| 2013 Q2 | 260.71 Million USD | 34.44% |
| 2013 Q1 | 193.93 Million USD | 149.75% |
| 2013 Q3 | 115.6 Million USD | -55.66% |
| 2013 FY | 143.99 Million USD | 85.43% |
| 2012 FY | 77.65 Million USD | -39.24% |
| 2012 Q1 | 158.19 Million USD | 23.79% |
| 2012 Q4 | 77.65 Million USD | 28.85% |
| 2012 Q2 | 11.4 Million USD | -92.79% |
| 2012 Q3 | 60.26 Million USD | 428.45% |
| 2011 Q3 | 109.87 Million USD | 33.98% |
| 2011 FY | 127.79 Million USD | 1253.43% |
| 2011 Q1 | 24.83 Million USD | 163.07% |
| 2011 Q2 | 82 Million USD | 230.14% |
| 2011 Q4 | 127.79 Million USD | 16.31% |
| 2010 Q4 | 9.44 Million USD | -91.39% |
| 2010 FY | 9.44 Million USD | -92.47% |
| 2010 Q3 | 109.71 Million USD | 6.36% |
| 2010 Q2 | 103.14 Million USD | 63.78% |
| 2010 Q1 | 62.98 Million USD | -49.78% |
| 2009 Q4 | 125.41 Million USD | 16.77% |
| 2009 FY | 125.41 Million USD | 55.49% |
| 2009 Q1 | 99.98 Million USD | 23.97% |
| 2009 Q2 | 111.93 Million USD | 11.95% |
| 2009 Q3 | 107.4 Million USD | -4.05% |
| 2008 Q3 | 43.99 Million USD | -48.47% |
| 2008 FY | 80.65 Million USD | 193.9% |
| 2008 Q1 | 91.73 Million USD | 206.79% |
| 2008 Q4 | 80.65 Million USD | 83.33% |
| 2008 Q2 | 85.37 Million USD | -6.92% |
| 2007 Q1 | -76.54 Million USD | -6.67% |
| 2007 FY | -85.89 Million USD | -19.7% |
| 2007 Q4 | -85.89 Million USD | -9.7% |
| 2007 Q3 | -78.3 Million USD | -74.14% |
| 2007 Q2 | -44.96 Million USD | 41.26% |
| 2006 FY | -71.76 Million USD | -49.78% |
| 2006 Q4 | -71.76 Million USD | 15.19% |
| 2006 Q3 | -84.62 Million USD | -1.18% |
| 2006 Q2 | -83.63 Million USD | 17.93% |
| 2006 Q1 | -101.91 Million USD | -112.71% |
| 2005 Q4 | -47.91 Million USD | -137.39% |
| 2005 Q2 | -61.38 Million USD | 25.41% |
| 2005 FY | -47.91 Million USD | 50.61% |
| 2005 Q3 | -20.18 Million USD | 67.12% |
| 2005 Q1 | -82.29 Million USD | 15.17% |
| 2004 Q4 | -97.01 Million USD | -197.73% |
| 2004 Q2 | -100.09 Million USD | 0.0% |
| 2004 Q3 | -32.58 Million USD | 67.45% |
| 2004 FY | -97.01 Million USD | -247.98% |
| 2003 FY | -27.87 Million USD | 61.68% |
| 2002 FY | -72.74 Million USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Caribou Biosciences, Inc. | -23.67 Million USD | 1179.372% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 3091.428% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 4315.82% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -1830.38% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 205.446% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 559.53% |
| Agenus Inc. | 274.13 Million USD | 6.775% |
| Fortress Biotech, Inc. | 7.66 Million USD | -3234.155% |
| GlycoMimetics, Inc. | -40.98 Million USD | 723.561% |
| Novavax, Inc. | -298.29 Million USD | 185.675% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 180.695% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 1703.985% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 167.754% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -40594.745% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | -317.198% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 86.333% |
| AlloVir, Inc. | -62.69 Million USD | 507.649% |
| Aptorum Group Limited | 1.35 Million USD | -18732.302% |
| Ardelyx, Inc. | 34.51 Million USD | -640.505% |
| Bicycle Therapeutics plc | -481.46 Million USD | 153.08% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | -606.697% |
| Chimerix, Inc. | -25.51 Million USD | 1101.54% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -3567.626% |
| CRISPR Therapeutics AG | -150.84 Million USD | 269.421% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -1714.949% |
| Precision BioSciences, Inc. | -85.41 Million USD | 399.219% |
| Dyadic International, Inc. | -6.37 Million USD | 4106.884% |
| Elevation Oncology, Inc. | -19.11 Million USD | 1436.766% |
| Fortress Biotech, Inc. | 7.66 Million USD | -3234.155% |
| GT Biopharma, Inc. | -1.02 Million USD | 25130.656% |
| Alkermes plc | -166.73 Million USD | 253.271% |
| Immix Biopharma, Inc. | -17.5 Million USD | 1559.543% |
| IO Biotech, Inc. | -140.69 Million USD | 281.638% |
| Jaguar Health, Inc. | 29.39 Million USD | -769.528% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 1622.205% |
| ContextLogic Inc. | -232 Million USD | 210.156% |
| AbCellera Biologics Inc. | -55.94 Million USD | 556.852% |
| Lantern Pharma Inc. | -21.7 Million USD | 1277.532% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 5306.009% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -5871.098% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -1379.124% |
| MEI Pharma, Inc. | -3.7 Million USD | 6997.787% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 297.936% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 1479.941% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 2602.085% |
| NextCure, Inc. | -6.47 Million USD | 4045.7% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 331.201% |
| ChromaDex Corporation | -24.04 Million USD | 1162.72% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 265.793% |
| Incyte Corporation | -3.17 Billion USD | 108.049% |
| Opthea Limited | 28.15 Million USD | -807.621% |
| MiMedx Group, Inc. | -33.9 Million USD | 853.851% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -2001.105% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 557.474% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -3606.714% |
| Vaxcyte, Inc. | -368.22 Million USD | 169.404% |
| PDS Biotechnology Corporation | -32.7 Million USD | 881.326% |
| Pharming Group N.V. | 109.8 Million USD | -132.745% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 1569.091% |
| Onconetix, Inc. | 5.33 Million USD | -4693.511% |
| Acelyrin, Inc. | -216.9 Million USD | 217.824% |
| PureTech Health plc | -167.19 Million USD | 252.851% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -2406.748% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 245.844% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 11129.781% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 1479.941% |
| ESSA Pharma Inc. | -33.62 Million USD | 860.116% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -819.523% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 606.055% |
| Seer, Inc. | -4.24 Million USD | 6127.429% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 3699.479% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 14923.84% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 4461.143% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 4655.273% |
| Summit Therapeutics Inc. | 34.67 Million USD | -637.045% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 3856.622% |
| Senti Biosciences, Inc. | 1.74 Million USD | -14587.529% |
| ImmuCell Corporation | 10.99 Million USD | -2225.295% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 429.967% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -4688.514% |
| Precigen, Inc. | -481 Thousand USD | 53231.601% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 1944.421% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 4106.318% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 238.436% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | -58.007% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -256054.717% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | -130.507% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 1163.207% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 318.344% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 939.012% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -1942.706% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 251.91% |
| Fate Therapeutics, Inc. | 61.66 Million USD | -314.431% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 3464.442% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 477.031% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 290.606% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 985.159% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 339339.918% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 928.083% |
| Aptose Biosciences Inc. | -8.19 Million USD | 3218.578% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 8267.515% |
| Soligenix, Inc. | -4.95 Million USD | 5261.224% |
| Century Therapeutics, Inc. | 847 Thousand USD | -30072.727% |
| Kura Oncology, Inc. | -20.11 Million USD | 1370.32% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 724.451% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 3143.141% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -13928.858% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 8093.838% |
| Autolus Therapeutics plc | -186.59 Million USD | 236.958% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 618.341% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 192.664% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -645.777% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | -55.482% |
| GRI Bio, Inc. | -1.79 Million USD | 14345.429% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 2944.948% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 868.449% |
| IGM Biosciences, Inc. | -72.6 Million USD | 451.986% |
| INmune Bio, Inc. | -25.41 Million USD | 1105.718% |
| Heron Therapeutics, Inc. | 150.95 Million USD | -69.302% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 604.477% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 1672.756% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 8958.563% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | -572.269% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 720.524% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -701.515% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 32.382% |
| Verastem, Inc. | -37.27 Million USD | 785.56% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 2916.742% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 592.775% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 1788.556% |
| Histogen Inc. | -7.48 Million USD | 3513.423% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 1282.789% |
| Surrozen, Inc. | -32.66 Million USD | 882.4% |
| Organovo Holdings, Inc. | -1.5 Million USD | 17058.394% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 6179.784% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -1247.891% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -9669.228% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -6049.254% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 3149.259% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 688.286% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 1853.21% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 180.673% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 35493.596% |
| Apollomics, Inc. | -27.39 Million USD | 1032.882% |
| Amarin Corporation plc | -191.04 Million USD | 233.775% |
| Mesoblast Limited | 55.96 Million USD | -356.664% |
| Turnstone Biologics Corp. | -14.58 Million USD | 1852.352% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 1110.45% |
| Synaptogenix, Inc. | -28.66 Million USD | 991.66% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 27403.739% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | -424.425% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 29744.619% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 3617.206% |
| Exelixis, Inc. | -73.05 Million USD | 449.847% |
| Better Therapeutics, Inc. | -860 Thousand USD | 29816.628% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 1164.269% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 205.88% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -34620.12% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 3535.848% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -20279.825% |
| Gritstone bio, Inc. | 39.49 Million USD | -547.159% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 403.876% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 9809.324% |
| Avid Bioservices, Inc. | 169.72 Million USD | -50.572% |
| Insmed Incorporated | 721.62 Million USD | 64.585% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 2895.632% |
| MediWound Ltd. | -5.32 Million USD | 4902.011% |
| OmniAb, Inc. | 9.2 Million USD | -2676.953% |
| Alector, Inc. | -35.63 Million USD | 817.128% |
| Seres Therapeutics, Inc. | 85.97 Million USD | -197.267% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 5285.938% |
| Zai Lab Limited | -775 Million USD | 132.976% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 24.957% |
| Aura Biosciences, Inc. | -21.52 Million USD | 1287.285% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 409.848% |
| Immunic, Inc. | -45.34 Million USD | 663.659% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 232.269% |
| Veracyte, Inc. | -203.82 Million USD | 225.384% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 59.962% |
| FibroGen, Inc. | 56.76 Million USD | -350.196% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -2769.882% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 9139.816% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 12443.963% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 94.433% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 7749.297% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 253.987% |
| TG Therapeutics, Inc. | 17.86 Million USD | -1330.764% |
| Galecto, Inc. | -21.21 Million USD | 1304.577% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 1174.471% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 83.716% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 1144.308% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 2320.935% |
| XBiotech Inc. | -200.02 Million USD | 227.767% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 403.876% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -5544.059% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 824.734% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 430.963% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -4390.652% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 249.965% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 376.661% |
| Vaxxinity, Inc. | 10.13 Million USD | -2422.335% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 65.289% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 2473.455% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 487.475% |
| NexImmune, Inc. | -3.13 Million USD | 8255.46% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 7501.888% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 1791.188% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 1043.037% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 2947.165% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 205247.903% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 729.9% |
| Ainos, Inc. | 4.07 Million USD | -6166.982% |
| Pluri Inc. | 22.82 Million USD | -1019.466% |
| Prothena Corporation plc | -608.34 Million USD | 142.009% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 315.2% |
| Celularity Inc. | 65.19 Million USD | -292.028% |
| Rallybio Corporation | -24.1 Million USD | 1160.339% |
| Cue Biopharma, Inc. | -33.81 Million USD | 855.679% |
| MeiraGTx Holdings plc | -40.3 Million USD | 734.12% |
| Omeros Corporation | 331.17 Million USD | 22.832% |
| Humacyte, Inc. | -22.48 Million USD | 1236.543% |
| Immunocore Holdings plc | -358.59 Million USD | 171.268% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 1139.931% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 927.038% |
| Blueprint Medicines Corporation | 702.83 Million USD | 63.638% |
| CalciMedica, Inc. | -5.53 Million USD | 4721.392% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 235.779% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 738.317% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 868.541% |
| Pulmatrix, Inc. | -10.41 Million USD | 2553.326% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 4375.774% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 770.03% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 329.406% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 526.336% |
| Cytokinetics, Incorporated | 642.37 Million USD | 60.216% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 4488.855% |
| Nutriband Inc. | -251.65 Thousand USD | 101652.113% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 849.034% |
| Vor Biopharma Inc. | 4.3 Million USD | -5843.326% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 104.234% |
| Evogene Ltd. | -19.63 Million USD | 1401.635% |
| ProKidney Corp. | -56.23 Million USD | 554.447% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 625.072% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 2866.676% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 81.262% |
| CorMedix Inc. | -43.05 Million USD | 693.608% |
| BioLineRx Ltd. | 7.33 Million USD | -3383.683% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 1030.504% |
| Galectin Therapeutics Inc. | 46.14 Million USD | -453.802% |
| Atai Life Sciences N.V. | -28.55 Million USD | 994.891% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -11357.506% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 1220.104% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -1341.009% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 440.415% |
| MediciNova, Inc. | -50.78 Million USD | 603.24% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 424.298% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 1136188.02% |
| GeoVax Labs, Inc. | -6.45 Million USD | 4060.627% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 227.896% |
| Biomea Fusion, Inc. | -166.57 Million USD | 253.427% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 242.793% |
| Mereo BioPharma Group plc | -51.46 Million USD | 596.538% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 369.456% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 186.998% |
| Absci Corporation | -72.59 Million USD | 452.025% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -5497.087% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 209.011% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 371.267% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 367.057% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 754.065% |
| Allakos Inc. | -24.97 Million USD | 1123.275% |
| Imunon, Inc. | -4.21 Million USD | 6164.831% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 1833.571% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 288.747% |
| BioAtla, Inc. | -109.01 Million USD | 334.438% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -34620.12% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 27316.507% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -2035.743% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 1305.315% |
| XOMA Corporation | -29 Million USD | 981.252% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 1643.255% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 2934.55% |
| aTyr Pharma, Inc. | -7.44 Million USD | 3530.836% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 305.047% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 222.77% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 412.504% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 375.501% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 29844.851% |
| Akari Therapeutics, Plc | -3.84 Million USD | 6746.632% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -15647.401% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 81.493% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 21609.593% |
| UroGen Pharma Ltd. | 4.39 Million USD | -5720.155% |
| Sutro Biopharma, Inc. | 113.48 Million USD | -125.203% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -355036.044% |
| Orgenesis Inc. | 21.78 Million USD | -1073.168% |
| Entera Bio Ltd. | -10.62 Million USD | 2504.394% |
| GH Research PLC | -78.07 Million USD | 427.322% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 1246.639% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 1058.637% |
| Xencor, Inc. | 29.64 Million USD | -762.107% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 13073.979% |
| Replimune Group, Inc. | 1.41 Million USD | -17999.363% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 104450.613% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 302.159% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 21609.593% |
| Portage Biotech Inc. | -4.98 Million USD | 5230.757% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 1136188.02% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 486.502% |
| OncoCyte Corporation | -6.56 Million USD | 3993.997% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -28377.747% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 5709.812% |
| Purple Biotech Ltd. | -14.13 Million USD | 1907.632% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 1175.783% |
| scPharmaceuticals Inc. | -6.54 Million USD | 4004.706% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 1631.036% |
| HilleVax, Inc. | -165.48 Million USD | 254.433% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 10169.464% |
| Tharimmune, Inc. | -10.93 Million USD | 2437.035% |
| Genprex, Inc. | -6.73 Million USD | 3893.07% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 169.295% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 388.902% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 18341.47% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 7804.768% |
| OKYO Pharma Limited | -826.84 Thousand USD | 31008.099% |
| Savara Inc. | 153 Thousand USD | -166934.641% |
| Curis, Inc. | -23.88 Million USD | 1169.883% |
| Daré Bioscience, Inc. | -5.15 Million USD | 5054.777% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 33032.867% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 4216.672% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -21466.498% |
| BeiGene, Ltd. | -2.25 Billion USD | 111.343% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -1971.265% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 142.019% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 237.706% |
| Erasca, Inc. | -37.21 Million USD | 786.702% |
| bluebird bio, Inc. | 108.57 Million USD | -135.388% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 19943.496% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 32.524% |
| DBV Technologies S.A. | -126.98 Million USD | 301.253% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 19943.496% |
| Moderna, Inc. | -2.9 Billion USD | 108.791% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 2568.731% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 2451.518% |
| Molecular Templates, Inc. | 707 Thousand USD | -36047.525% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 914.647% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 26.267% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 411.427% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 378.604% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 891.903% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 843.434% |
| MacroGenics, Inc. | -66.98 Million USD | 481.523% |
| RenovoRx, Inc. | -1.17 Million USD | 21887.127% |
| Adicet Bio, Inc. | -138.78 Million USD | 284.14% |
| Prime Medicine, Inc. | -27.94 Million USD | 1014.652% |
| Aditxt, Inc. | 18.12 Million USD | -1310.323% |
| Adagene Inc. | -87.62 Million USD | 391.647% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 6235.336% |
| Quantum-Si incorporated | -118.55 Million USD | 315.561% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | -609.799% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 3519.274% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 626.836% |
| SciSparc Ltd. | -2.06 Million USD | 12475.932% |
| Vericel Corporation | 1.27 Million USD | -19912.764% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 2231.166% |
| Minerva Neurosciences, Inc. | 41 Million USD | -523.26% |
| Generation Bio Co. | 31.44 Million USD | -712.653% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 245.733% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 926.45% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | -119.192% |
| Invivyd, Inc. | -198.47 Million USD | 228.763% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 383.11% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 10758.725% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 461.016% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 3844.513% |
| 2seventy bio, Inc. | 181.71 Million USD | -40.639% |
| ADMA Biologics, Inc. | 90.06 Million USD | -183.751% |
| Clene Inc. | 3.34 Million USD | -7551.587% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 2913.733% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 1288.057% |
| GeoVax Labs, Inc. | -6.45 Million USD | 4060.627% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 174.265% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 1082.947% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | -43.845% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 6346.091% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -5009.216% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 5006.182% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 296.128% |
| Evaxion Biotech A/S | 5.28 Million USD | -4733.943% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 327.03% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 294.681% |
| Trevena, Inc. | 2.25 Million USD | -11218.113% |
| Surrozen, Inc. | -32.66 Million USD | 882.4% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 596.142% |
| Cingulate Inc. | 3.08 Million USD | -8190.278% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 8801.498% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -3455.906% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 2850.584% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 422.18% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 294.415% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 342.143% |
| Clearmind Medicine Inc. | -3.94 Million USD | 6582.032% |
| Kronos Bio, Inc. | -36.05 Million USD | 808.834% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -2616.155% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -17426.8% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 571.032% |
| Statera Biopharma, Inc. | 14.41 Million USD | -1672.723% |
| ImmunityBio, Inc. | 618.22 Million USD | 58.662% |
| Korro Bio, Inc. | -132.94 Million USD | 292.235% |
| Kineta, Inc. | -4.54 Million USD | 5727.901% |
| BioVie Inc. | -17.73 Million USD | 1541.225% |
| Codexis, Inc. | -43.27 Million USD | 690.61% |
| Celularity Inc. | 65.19 Million USD | -292.028% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 8164.468% |
| Celcuity Inc. | 6.78 Million USD | -3667.416% |
| Virax Biolabs Group Limited | -3.36 Million USD | 7694.866% |
| Cibus, Inc. | -8.07 Million USD | 3263.692% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 6143.107% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -5492.188% |
| IN8bio, Inc. | -16.38 Million USD | 1659.357% |
| Kodiak Sciences Inc. | -103.87 Million USD | 346.029% |
| Annexon, Inc. | -193.75 Million USD | 231.9% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -709797.222% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 1560.443% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 7374.779% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 75.759% |
| Eyenovia, Inc. | 1.25 Million USD | -20203.694% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -849.872% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 7980.45% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 868.68% |
| Arcellx, Inc. | -296.95 Million USD | 186.06% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 1410.176% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 534.077% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 1332.996% |
| Moolec Science SA | 117.61 Thousand USD | -217185.913% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 765.546% |
| Geron Corporation | 14.76 Million USD | -1631.339% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 773.989% |
| Royalty Pharma plc | 5.65 Billion USD | 95.483% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 280.711% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 3756.424% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 4865.425% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 281.597% |
| Humacyte, Inc. | -22.48 Million USD | 1236.543% |
| Structure Therapeutics Inc. | -124.33 Million USD | 305.537% |
| 89bio, Inc. | -289.05 Million USD | 188.414% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 1112.451% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 14433.315% |
| Genelux Corporation | -6.89 Million USD | 3804.348% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 922.831% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | -205.701% |
| Notable Labs, Ltd. | -9.77 Million USD | 2714.188% |
| Liquidia Corporation | -80.17 Million USD | 418.752% |
| Mustang Bio, Inc. | -3.73 Million USD | 6940.551% |
| Immunovant, Inc. | -635.22 Million USD | 140.232% |
| Quantum-Si incorporated | -118.55 Million USD | 315.561% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 1555.039% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 6268.549% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -3083.792% |
| Acasti Pharma Inc. | -23 Million USD | 1210.902% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 7689.712% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 1672.756% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 285.54% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 8300.684% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 1249.528% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 1476.288% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 250.972% |
| PepGen Inc. | -60.67 Million USD | 521.235% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 1212.304% |
| United Therapeutics Corporation | -507.7 Million USD | 150.337% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 1436.207% |
| Solid Biosciences Inc. | -47.75 Million USD | 635.21% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 29744.619% |
| Immuneering Corporation | -54.94 Million USD | 565.143% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 6179.784% |
| Silo Pharma, Inc. | -3.52 Million USD | 7351.438% |
| Belite Bio, Inc | -87.27 Million USD | 392.838% |
| XOMA Corporation | -29 Million USD | 981.252% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 461.491% |
| Bionomics Limited | 227 Million USD | -12.578% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 319.779% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 10189.341% |
| uniQure N.V. | -102.95 Million USD | 348.238% |
| Cassava Sciences, Inc. | -121.13 Million USD | 310.972% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 6235.336% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | -524.07% |
| Forte Biosciences, Inc. | -11.96 Million USD | 2236.636% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 8359.421% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -240997.17% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 7980.45% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -2769.882% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 3546.103% |
| Altimmune, Inc. | -134.48 Million USD | 290.028% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -29.03% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 10189.341% |
| Compugen Ltd. | -12.9 Million USD | 2080.494% |
| Peak Bio, Inc. | 10.34 Million USD | -2371.558% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 90404.947% |
| Benitec Biopharma Inc. | -50.58 Million USD | 605.245% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 344.938% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -1200.906% |
| Zura Bio Limited | -99.8 Million USD | 356.06% |
| PolyPid Ltd. | 6.17 Million USD | -4042.026% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | -244.796% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -1200.906% |
| Instil Bio, Inc. | 75.35 Million USD | -239.132% |
| argenx SE | -2.02 Billion USD | 112.596% |
| Immunome, Inc. | -97.02 Million USD | 363.388% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 1236.088% |
| Verona Pharma plc | -220.44 Million USD | 215.932% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 456.22% |
| Shattuck Labs, Inc. | -121.42 Million USD | 310.472% |
| CervoMed Inc. | -7.79 Million USD | 3379.457% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 237.771% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 5944.112% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 293.99% |
| Moolec Science SA | 117.61 Thousand USD | -217185.913% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 11269.824% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -1507.478% |
| AnaptysBio, Inc. | -18.15 Million USD | 1507.983% |
| Design Therapeutics, Inc. | -18.15 Million USD | 1508.061% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 463.114% |
| NeurAxis, Inc. | 145.7 Thousand USD | -175303.569% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -2175.312% |
| Lumos Pharma, Inc. | -28.49 Million USD | 996.933% |
| Achilles Therapeutics plc | -126.92 Million USD | 301.351% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 456.22% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 39073.815% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 1330.216% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -17426.8% |
| Nutriband Inc. | -251.65 Thousand USD | 101652.113% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 2040.346% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 3534.987% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 24.878% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -976.735% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 157.113% |
| Palisade Bio, Inc. | -12.06 Million USD | 2218.569% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 282.14% |
| Beam Therapeutics Inc. | -262.72 Million USD | 197.275% |
| Neurogene Inc. | -131.95 Million USD | 293.674% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -1071.448% |
| AEON Biopharma, Inc. | -4.88 Million USD | 5336.947% |
| Sesen Bio, Inc. | -112.55 Million USD | 327.06% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 355.921% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 10985.244% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 754.853% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 406.865% |
| Athira Pharma, Inc. | -88.99 Million USD | 387.153% |
| Vaccinex, Inc. | -1.28 Million USD | 19941.848% |
| HCW Biologics Inc. | 2.85 Million USD | -8846.167% |
| XOMA Corporation | -29 Million USD | 981.252% |
| Nektar Therapeutics | 210.24 Million USD | -21.558% |
| Arvinas, Inc. | -313.8 Million USD | 181.441% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -15647.401% |
| Merus N.V. | -192.88 Million USD | 232.496% |
| Omega Therapeutics, Inc. | 59.98 Million USD | -326.045% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 3783.526% |
| Rezolute, Inc. | -68.16 Million USD | 474.902% |
| Clene Inc. | 3.34 Million USD | -7551.587% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 2037.992% |
| BeyondSpring Inc. | -13.75 Million USD | 1957.964% |
| Synlogic, Inc. | -6.68 Million USD | 3922.932% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -22436.42% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 3122.626% |
| Peak Bio, Inc. | 10.34 Million USD | -2371.558% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 410.074% |
| Krystal Biotech, Inc. | -350.23 Million USD | 172.969% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | -105.892% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 251.224% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 8194.753% |
| MannKind Corporation | 143.89 Million USD | -77.599% |
| Ikena Oncology, Inc. | -109.15 Million USD | 334.126% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 3475.551% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 872.094% |
| Gossamer Bio, Inc. | 180.35 Million USD | -41.7% |
| CohBar, Inc. | -5.93 Million USD | 4409.132% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 959.093% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -5497.087% |
| Legend Biotech Corporation | -949.39 Million USD | 126.918% |
| Mural Oncology plc | -255.84 Million USD | 199.891% |
| Biora Therapeutics, Inc. | 32.21 Million USD | -693.304% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 5525.227% |
| Disc Medicine, Inc. | -358.28 Million USD | 171.33% |
| Champions Oncology, Inc. | 4.81 Million USD | -5210.952% |
| REGENXBIO Inc. | 54.76 Million USD | -366.628% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 95137.69% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 269.22% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 2935.806% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 416.75% |
| Vaxart, Inc. | -8.24 Million USD | 3201.116% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 609.293% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 300.969% |
| Cellectis S.A. | -43.85 Million USD | 682.745% |
| Longeveron Inc. | -2.9 Million USD | 8888.274% |
| Repare Therapeutics Inc. | -107.85 Million USD | 336.944% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 73.609% |
| Inozyme Pharma, Inc. | 12 Million USD | -2028.982% |
| Revolution Medicines, Inc. | -608.2 Million USD | 142.019% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 20877.48% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 196.396% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 270.294% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 1733.304% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 34635.541% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 102.672% |
| Denali Therapeutics Inc. | -74.86 Million USD | 441.365% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 2231.166% |
| Veru Inc. | 4.77 Million USD | -5246.541% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 2372.479% |
| Cingulate Inc. | 3.08 Million USD | -8190.278% |
| Passage Bio, Inc. | 4.58 Million USD | -5473.893% |
| Context Therapeutics Inc. | -14.44 Million USD | 1868.623% |
| Exicure, Inc. | 5.84 Million USD | -4269.345% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 210.933% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 745.85% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -1528.723% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 534.476% |
| Nuvalent, Inc. | -335.38 Million USD | 176.199% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -14635.453% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 443.12% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 2974.724% |
| OmniAb, Inc. | 9.2 Million USD | -2676.953% |
| Anew Medical, Inc. | 1.43 Million USD | -17740.785% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -1460.047% |
| Lipocine Inc. | -4.75 Million USD | 5475.077% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 332.694% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -1577.913% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 604.477% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -926.687% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 3902.455% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 488.234% |
| Ocugen, Inc. | -32.52 Million USD | 885.84% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 398.642% |
| Q32 Bio Inc. | -37.94 Million USD | 773.456% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 40794.745% |
| Alumis Inc. Common Stock | -13.52 Million USD | 1989.001% |
| Equillium, Inc. | -22.39 Million USD | 1241.314% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 1099.542% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 883.292% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 103184.928% |
| Galera Therapeutics, Inc. | 134.04 Million USD | -90.659% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -7891.338% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -77710.931% |
| Dominari Holdings Inc. | 195 Thousand USD | -130957.949% |
| Edesa Biotech, Inc. | -5.26 Million USD | 4952.238% |
| vTv Therapeutics Inc. | -8.91 Million USD | 2966.02% |
| Bio-Techne Corporation | 267.74 Million USD | 4.551% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 1676.673% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 316.406% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 3141.33% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 2120.101% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 204.261% |
| Nkarta, Inc. | 57.29 Million USD | -346.017% |
| BioCardia, Inc. | 212 Thousand USD | -120448.585% |
| Iterum Therapeutics plc | 13.43 Million USD | -1801.793% |